Molecular exploration

The ICM's platforms provide scientific support to researchers at all stages of their projects: from the molecule to the individual. These platforms are grouped into six thematic clusters, called silos. 
Open / close summary

The molecular exploration silo is structured around the genotyping-sequencing platform called iGenSeq. 






Scientific manager : Stéphanie BAULAC (PhD, DR2, INSERM) 

Operational manager : Yannick MARIE (Engineer) 


iGenSeq provides tools and services for genome analysis to academics or industrials. More specifically, services include real-time PCR, digital PCR, sequencing, as well as purification and analysis of nucleic acids. Each project submitted to the core facility is discussed with the investigator to optimize the design and the feasibility. This platform masters the techniques of highthroughput sequencing and can provide new generation sequencing. 











Vectorology core facility.


Scientific manager: Philippe RAVASSARD (PhD, CR1, CNRS)

Operational manager: To be determined

The Vector core facility produces viral tools for gene transfer highly concentrated under different scales. iVector is specialized in lentiviral systems as it benefits in house from the experience of the biotechnology and biotherapy Institut du Cerveau – ICM/CNRS team. Since the use of adenoviruses and AAV systems in the field of research in neurobiology is constantly increasing, iVector has developed production of AAV serotypes 2, retro2 & 9 as well as canine adenovirus CAV-2 in addition to its lentiviral system. iVector is making these tools available for any academic and industrial partner. iVector implements continuously in his services portfolio gene transfer innovative technologies (ie: CRISPRs, Split-reporters, DNA/RNA based libraries, …) to allow new approaches in basic research and lead to new applications in genetic engineering, curative and regenerative medicine (gene and cell therapy, tissue engineering and vaccines). iVector premises for production and manipulation of viral particles were designed to match both Biosafety Level 2 (BSL2) and Biosafety Level 3 (BSL3) in accordance to national and European regulations. We have access to, we develop, a large and various collection of viral vectors that allows us to provide quickly a tailored solution that fits researchers’ needs for their in vitro and in vivo applications.